Publications

HRA Pharma has collaborated on a number of scientific publications in the areas of women’s health and endocrinology – whether through scientific cooperation or sponsorship.

filter by theme
Women's health
Endocrinology
Academic support
Non clinical
 contact us

Publications

HRA Pharma has collaborated on a number of scientific publications in the areas of women’s health and endocrinology – whether through scientific cooperation or sponsorship.

Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception
Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Obstetrics & Gynecology. 115(2, Part 1):257-263, February 2010
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis
Glasier A, Cameron S, Fine P, Logan S, Casale W, Van Horn J, Sogor L, Blithe D, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Lancet. 2010 Feb 13;375(9714):555-62
Ulipristal acetate in uterine fibroids.
Croxtall Jamie D. Adis Drug Profile. 2012 ;72(8) :1075-1085.
Ulipristal acetate versus placebo for fibroid treatment before surgery. Donnez J et al for the PEARL I Study Group.
N Engl J Med 2012;366:409-420.
Ulipristal acetate versus leuprolide acetate for uterine fibroids. Donnez J et al for the PEARL II Study Group. N Engl J
Med 2012;366:421-432.
Long-term treatment of uterine fibroids with ulipristal acetate. Donnez J et al. for the PEARL III and PEARL III Extension Study Group.
Feril Steril 2014. In press.
Ulipristal acetate, a review of its use in emergency contraception.
Adis Drug Evaluation 2011;71(7):935-945.
Ulipristal acetate for emergency contraception: post-marketing experience after use by more than 1 million women.
DP Levy, M Jager, N Kapp, JL Abitbol. Contraception 2014. In press.
closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?